Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2011. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) rather than a comprehensive financial results announcement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting a specific share transaction.
Material Changes
The only material change reported is a reduction in shareholding by a senior executive:
- Executive: Mr. J R Stéphenne
- Transaction: Sale of 20,000 Ordinary shares
- Date: December 21, 2011
- Price: £14.408 per share
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies. It strictly adheres to Disclosure Rule 3.1.4R(1)(a) regarding the notification of the share sale.
Investor Verification Checklist
- Verify the total remaining shareholding of Mr. J R Stéphenne following this sale.
- Confirm the market price of GSK shares on December 21, 2011, to contextualize the sale price of £14.408.
- Review the company's full annual report (Form 20-F) for the 2011 fiscal year to obtain actual financial performance data.